As the signs point toward a potential Evotec acquisition, delve into what it could represent for the European biotech ...

San Diego biotech firm Halozyme Therapeutics is walking back its proposed $2.1 billion acquisition of Evotec, saying the ...

Halozyme Therapeutics has withdrawn its $2.1 billion offer to buy Evotec after the German company “has been unwilling to ...

Halozyme Therapeutics (NASDAQ:HALO) fell 14% after confirming on Thursday that it made an €11 per share bid for Evotec (EVO).

Evotec's COO Craig Johnstone will leave by year-end as the company implements its Priority Reset restructuring amid declining ...

Evotec (EVO) announced that its Chief Operating Officer, Dr Craig Johnstone, will step down and leave the company effective December 31. Dr Johnstone joined Evotec in May 2012 as SVP Drug Discovery ...

Halozyme's strategic acquisition of Evotec and innovative ENHANZE technology present growth opportunities. Click here for a ...

Halozyme made the €11-per-share offer earlier this month, valuing Evotec at around €2 billion ($2.1 billion), saying at the ...

(Bloomberg) -- Evotec SE has attracted takeover interest from Nasdaq-listed biotech firm Halozyme Therapeutics Inc. for a ...

Halozyme Therapeutics, a San Diego-based biopharmaceutical company, has made a $2.1 billion bid to buy German drugmaker ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) saw its shares rise on Friday after the company announced it was withdrawing its ...

We recently compiled a list of the 10 Best German Stocks To Buy Now. In this article, we are going to take a look at where ...